Lv5
1470 积分 2025-07-27 加入
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
2天前
已完结
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
2天前
已关闭
Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review
2天前
已完结
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
7天前
已完结
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial
11天前
已完结
中国肿瘤药物相关血小板减少诊疗专家共识（2023版）
13天前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
14天前
已完结
A study protocol of a single-arm, prospective, open-label, non-controlled, phase II study of neoadjuvant BL-B01D1 combined with aumolertinib in resectable stage II-IIIB non-small cell lung cancer patients with EGFR mutation
15天前
已完结
Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial
24天前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
25天前
已完结
皖公网安备34019202002308
